Share Price and Basic Stock Data
Last Updated: November 12, 2025, 5:46 pm
| PEG Ratio | -5.74 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dev Labtech Venture Ltd, operating in an unspecified industry, reported a share price of ₹61.0 and a market capitalization of ₹72.4 Cr. The company’s revenue from operations has shown a steady upward trajectory, with sales rising from ₹26.98 Cr in FY 2022 to ₹30.34 Cr in FY 2023, and further increasing to ₹43.22 Cr in FY 2024. By FY 2025, sales are projected to reach ₹52.41 Cr, indicating a robust growth strategy. Quarterly sales figures also reflect this trend, with ₹20.68 Cr recorded in March 2023 and ₹22.30 Cr in March 2024. The operating profit margin (OPM) stood at 5.68%, which is relatively low compared to industry averages, indicating potential areas for improvement. The company’s cash conversion cycle (CCC) has expanded significantly to 313.45 days, suggesting challenges in managing working capital effectively, which could impact liquidity and operational efficiency.
Profitability and Efficiency Metrics
Dev Labtech’s profitability metrics illustrate a mixed performance. The return on equity (ROE) was reported at a modest 3.85%, while the return on capital employed (ROCE) stood at 5.70%, both indicating underperformance against typical sector benchmarks. The net profit for FY 2025 was recorded at ₹1.29 Cr, with an earnings per share (EPS) of ₹1.14, down from ₹1.62 in FY 2024. The interest coverage ratio (ICR) was notably strong at 25.49x, highlighting the company’s ability to meet its interest obligations comfortably. However, the operating profit has shown fluctuations, with a peak OPM of 10.56% in September 2022, subsequently declining to 5.68% in FY 2025. This inconsistency in profitability signals potential operational inefficiencies that may require management’s immediate attention to stabilize earnings.
Balance Sheet Strength and Financial Ratios
Dev Labtech’s balance sheet reflects a conservative financial structure, with total borrowings recorded at ₹1.07 Cr against total liabilities of ₹43.77 Cr. The company maintains substantial reserves of ₹29.87 Cr, providing a cushion for future investments and operational needs. The current ratio is exceptionally high at 29.54, indicating excellent short-term liquidity. However, the price-to-book value (P/BV) ratio of 1.63x suggests that the stock might be overvalued compared to its book value, which stood at ₹36.42 per share. The asset turnover ratio of 1.45% is relatively low, suggesting inefficiencies in asset utilization that could hinder revenue generation. Overall, while the company exhibits strong liquidity and minimal debt, the efficiency of asset management remains a concern that could affect long-term growth prospects.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dev Labtech reveals a significant level of promoter ownership, which stood at 56.69% as of April 2025. This high promoter stake can instill confidence among retail investors, often viewed as a positive indicator of commitment to the company’s growth. The public shareholding accounted for 43.31%, with the total number of shareholders reported at 838. Notably, promoter shareholding has fluctuated, decreasing from 68.01% in March 2023 to 54.55% in March 2025, potentially raising concerns about dilution and investor confidence. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may suggest a lack of broader market interest, which could impact stock liquidity and price stability. The shifting dynamics in shareholding require close monitoring to gauge market sentiment and investor confidence moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Dev Labtech faces both opportunities and challenges. The company’s strong liquidity position and low debt levels provide a solid foundation for future growth initiatives. However, the elevated cash conversion cycle and fluctuating profitability metrics pose considerable risks that management must address to enhance operational efficiency. Additionally, the declining promoter stake may lead to reduced market confidence if not managed carefully. The company’s ability to stabilize its profit margins and improve asset utilization will be crucial in attracting institutional investors and enhancing shareholder value. If Dev Labtech can successfully navigate these challenges, it may unlock significant growth potential; conversely, failure to address these issues could hinder its long-term viability in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dev Labtech Venture Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 126 Cr. | 32.7 | 869/26.8 | 1.22 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 1,675 Cr. | 165 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 50.8 Cr. | 3.98 | 8.90/3.95 | 5.12 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,757.91 Cr | 251.13 | 355.74 | 102.45 | 0.23% | 11.73% | 22.92% | 9.18 |
Quarterly Result
| Metric | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 19.43 | 9.66 | 20.68 | 20.92 | 22.30 | 19.51 | 32.90 |
| Expenses | 18.99 | 8.64 | 19.80 | 18.82 | 21.53 | 18.30 | 31.03 |
| Operating Profit | 0.44 | 1.02 | 0.88 | 2.10 | 0.77 | 1.21 | 1.87 |
| OPM % | 2.26% | 10.56% | 4.26% | 10.04% | 3.45% | 6.20% | 5.68% |
| Other Income | 0.11 | 0.16 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest | 0.06 | 0.05 | 0.05 | 0.07 | 0.05 | 0.05 | 0.07 |
| Depreciation | 0.04 | 0.27 | 0.29 | 0.46 | 0.47 | 0.50 | 0.61 |
| Profit before tax | 0.45 | 0.86 | 0.54 | 1.58 | 0.25 | 0.66 | 1.19 |
| Tax % | 15.56% | 34.88% | 18.52% | 17.09% | 88.00% | 25.76% | 31.93% |
| Net Profit | 0.37 | 0.57 | 0.45 | 1.31 | 0.03 | 0.48 | 0.81 |
| EPS in Rs | 2.94 | 1.17 | 0.54 | 1.58 | 0.04 | 0.46 | 0.72 |
Last Updated: May 31, 2025, 6:19 am
Below is a detailed analysis of the quarterly data for Dev Labtech Venture Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 32.90 Cr.. The value appears strong and on an upward trend. It has increased from 19.51 Cr. (Sep 2024) to 32.90 Cr., marking an increase of 13.39 Cr..
- For Expenses, as of Mar 2025, the value is 31.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.30 Cr. (Sep 2024) to 31.03 Cr., marking an increase of 12.73 Cr..
- For Operating Profit, as of Mar 2025, the value is 1.87 Cr.. The value appears strong and on an upward trend. It has increased from 1.21 Cr. (Sep 2024) to 1.87 Cr., marking an increase of 0.66 Cr..
- For OPM %, as of Mar 2025, the value is 5.68%. The value appears to be declining and may need further review. It has decreased from 6.20% (Sep 2024) to 5.68%, marking a decrease of 0.52%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 0.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.05 Cr. (Sep 2024) to 0.07 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.50 Cr. (Sep 2024) to 0.61 Cr., marking an increase of 0.11 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.66 Cr. (Sep 2024) to 1.19 Cr., marking an increase of 0.53 Cr..
- For Tax %, as of Mar 2025, the value is 31.93%. The value appears to be increasing, which may not be favorable. It has increased from 25.76% (Sep 2024) to 31.93%, marking an increase of 6.17%.
- For Net Profit, as of Mar 2025, the value is 0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.48 Cr. (Sep 2024) to 0.81 Cr., marking an increase of 0.33 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.72. The value appears strong and on an upward trend. It has increased from 0.46 (Sep 2024) to 0.72, marking an increase of 0.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:31 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 11.79 | 12.24 | 26.98 | 30.34 | 43.22 | 52.41 |
| Expenses | 11.41 | 11.96 | 26.28 | 28.43 | 40.35 | 49.33 |
| Operating Profit | 0.38 | 0.28 | 0.70 | 1.91 | 2.87 | 3.08 |
| OPM % | 3.22% | 2.29% | 2.59% | 6.30% | 6.64% | 5.88% |
| Other Income | 0.00 | 0.04 | 0.12 | 0.16 | 0.01 | 0.00 |
| Interest | 0.18 | 0.16 | 0.14 | 0.10 | 0.12 | 0.12 |
| Depreciation | 0.15 | 0.11 | 0.09 | 0.55 | 0.93 | 1.11 |
| Profit before tax | 0.05 | 0.05 | 0.59 | 1.42 | 1.83 | 1.85 |
| Tax % | 100.00% | 40.00% | 16.95% | 27.46% | 26.78% | 29.73% |
| Net Profit | 0.00 | 0.04 | 0.49 | 1.02 | 1.34 | 1.29 |
| EPS in Rs | 0.00 | 1.91 | 3.90 | 1.23 | 1.62 | 1.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1125.00% | 108.16% | 31.37% | -3.73% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1016.84% | -76.79% | -35.10% |
Dev Labtech Venture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 25% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:11 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 70.28 | 89.16 | 55.20 | 56.54 | 16.13 | 33.43 |
| Inventory Days | 191.01 | 123.38 | 48.27 | 122.84 | 208.18 | 285.06 |
| Days Payable | 192.65 | 160.22 | 85.88 | 33.95 | 5.37 | 5.04 |
| Cash Conversion Cycle | 68.63 | 52.32 | 17.58 | 145.43 | 218.94 | 313.45 |
| Working Capital Days | 46.44 | 56.36 | 33.28 | 119.58 | 183.94 | 261.02 |
| ROCE % | 6.71% | 18.99% | 11.69% | 8.32% | 5.70% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.62 | 1.62 | 0.96 | 3.47 | 1.74 |
| Diluted EPS (Rs.) | 1.62 | 1.62 | 0.96 | 3.47 | 1.74 |
| Cash EPS (Rs.) | 2.13 | 2.75 | 1.90 | 4.16 | 6.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.42 | 31.16 | 22.83 | 15.28 | 70.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.42 | 31.16 | 22.83 | 15.28 | 70.86 |
| Revenue From Operations / Share (Rs.) | 46.37 | 52.26 | 36.68 | 213.58 | 584.18 |
| PBDIT / Share (Rs.) | 2.72 | 3.48 | 2.31 | 5.42 | 15.30 |
| PBIT / Share (Rs.) | 1.74 | 2.36 | 1.64 | 4.74 | 10.20 |
| PBT / Share (Rs.) | 1.63 | 2.21 | 1.70 | 3.63 | 2.61 |
| Net Profit / Share (Rs.) | 1.14 | 1.62 | 1.23 | 3.47 | 1.74 |
| PBDIT Margin (%) | 5.86 | 6.66 | 6.29 | 2.53 | 2.61 |
| PBIT Margin (%) | 3.75 | 4.50 | 4.46 | 2.21 | 1.74 |
| PBT Margin (%) | 3.52 | 4.23 | 4.64 | 1.69 | 0.44 |
| Net Profit Margin (%) | 2.46 | 3.10 | 3.35 | 1.62 | 0.29 |
| Return on Networth / Equity (%) | 3.14 | 5.20 | 5.39 | 22.71 | 2.45 |
| Return on Capital Employeed (%) | 4.63 | 7.22 | 6.77 | 19.08 | 7.35 |
| Return On Assets (%) | 2.95 | 4.67 | 4.29 | 4.91 | 0.51 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.05 | 0.59 | 0.93 |
| Total Debt / Equity (X) | 0.02 | 0.04 | 0.05 | 0.63 | 1.20 |
| Asset Turnover Ratio (%) | 1.45 | 1.65 | 1.86 | 3.35 | 1.72 |
| Current Ratio (X) | 29.54 | 14.01 | 5.24 | 1.44 | 1.45 |
| Quick Ratio (X) | 5.02 | 2.28 | 3.18 | 0.90 | 0.77 |
| Inventory Turnover Ratio (X) | 2.09 | 0.16 | 0.83 | 8.34 | 1.03 |
| Interest Coverage Ratio (X) | 25.49 | 24.43 | 18.29 | 4.89 | 2.02 |
| Interest Coverage Ratio (Post Tax) (X) | 11.72 | 12.38 | 9.23 | 3.31 | 1.23 |
| Enterprise Value (Cr.) | 68.16 | 83.64 | 37.44 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.30 | 1.94 | 1.23 | 0.00 | 0.00 |
| EV / EBITDA (X) | 22.16 | 29.04 | 19.60 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.28 | 1.91 | 1.39 | 0.00 | 0.00 |
| Price / BV (X) | 1.63 | 3.21 | 2.23 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.28 | 1.91 | 1.39 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dev Labtech Venture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.62. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 1.62.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.62. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 1.62.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 3. It has decreased from 2.75 (Mar 24) to 2.13, marking a decrease of 0.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.42. It has increased from 31.16 (Mar 24) to 36.42, marking an increase of 5.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.42. It has increased from 31.16 (Mar 24) to 36.42, marking an increase of 5.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 46.37. It has decreased from 52.26 (Mar 24) to 46.37, marking a decrease of 5.89.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 2.72, marking a decrease of 0.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.36 (Mar 24) to 1.74, marking a decrease of 0.62.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.63, marking a decrease of 0.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 1.62 (Mar 24) to 1.14, marking a decrease of 0.48.
- For PBDIT Margin (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 10. It has decreased from 6.66 (Mar 24) to 5.86, marking a decrease of 0.80.
- For PBIT Margin (%), as of Mar 25, the value is 3.75. This value is below the healthy minimum of 10. It has decreased from 4.50 (Mar 24) to 3.75, marking a decrease of 0.75.
- For PBT Margin (%), as of Mar 25, the value is 3.52. This value is below the healthy minimum of 10. It has decreased from 4.23 (Mar 24) to 3.52, marking a decrease of 0.71.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 3.10 (Mar 24) to 2.46, marking a decrease of 0.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 15. It has decreased from 5.20 (Mar 24) to 3.14, marking a decrease of 2.06.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.63. This value is below the healthy minimum of 10. It has decreased from 7.22 (Mar 24) to 4.63, marking a decrease of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 4.67 (Mar 24) to 2.95, marking a decrease of 1.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.45. It has decreased from 1.65 (Mar 24) to 1.45, marking a decrease of 0.20.
- For Current Ratio (X), as of Mar 25, the value is 29.54. This value exceeds the healthy maximum of 3. It has increased from 14.01 (Mar 24) to 29.54, marking an increase of 15.53.
- For Quick Ratio (X), as of Mar 25, the value is 5.02. This value exceeds the healthy maximum of 2. It has increased from 2.28 (Mar 24) to 5.02, marking an increase of 2.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 4. It has increased from 0.16 (Mar 24) to 2.09, marking an increase of 1.93.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 25.49. This value is within the healthy range. It has increased from 24.43 (Mar 24) to 25.49, marking an increase of 1.06.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 12.38 (Mar 24) to 11.72, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 68.16. It has decreased from 83.64 (Mar 24) to 68.16, marking a decrease of 15.48.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.94 (Mar 24) to 1.30, marking a decrease of 0.64.
- For EV / EBITDA (X), as of Mar 25, the value is 22.16. This value exceeds the healthy maximum of 15. It has decreased from 29.04 (Mar 24) to 22.16, marking a decrease of 6.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.28, marking a decrease of 0.63.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 3.21 (Mar 24) to 1.63, marking a decrease of 1.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.28, marking a decrease of 0.63.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dev Labtech Venture Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.63% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.14% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 56.3 (Industry average Stock P/E: 355.74)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Gems, Jewellery & Precious Metals | GF/22-23, Pattani Plaza, Bhavnagar Gujarat 364002 | cs@devlabtechventure.com http://www.devlabtechventure.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jerambhai Lavjibhai Donda | Chairman & Managing Director |
| Mr. Jay Jerambhai Donda | WholeTime Director & CFO |
| Mrs. Dimple Jay Donda | Non Executive Director |
| Mr. Vivekbhai Tulsibhai Mavani | Independent Director |
| Mr. Brijeshkumar Maheshbhai Pathak | Independent Director |